(A) T47D-eGFP, HCC1954-eGFP, HCC1937-eGFP, CAL-120-eGPF, MDA-MB-231-eGPF, and MCF10A-eGPF were infected with shRNAs targeting the indicated genes. Cells were then treated with GDC0941 (0.5, 1.25, 1, 0.312, 0.312, and 0.156 μM, respectively) or vehicle (DMSO) for 9 days. Z-scores for the fold-change of proliferation were calculated based on control shRNAs. Bars indicate standard deviation between the different shRNAs targeting each gene. Data shown are representative of at least two independent experiments. (B) T47D-eGFP, HCC1954-eGFP, HCC1937-eGFP, and SKBR3-eGFP were treated for 9 days with the indicated inhibitors (0.01–10 μM) combined with GDC0941 (0.5, 1.25, 1, and 0.625 μM, respectively; red), or vehicle (DMSO; blue). Plotted are mean and standard deviation of fold-change of proliferation from 4 replicates. Expected effect of combination treatment (gray) was calculated as in Figure 2. Significant synergistic combinations according to Bliss independence model are indicated by asterisks.